Missed the Gilead Surge? Here’s What You Need to Know About the Big Move
In late June, Gilead Sciences (GILD) stock surged following positive results of a late-stage trial for its latest HIV drug. ...
Latest News
Nvidia Breaks the 50-day SMA – Is this a Threat or an Opportunity?
After a big run this year, Nvidia (NVDA) fell over 15% from its high and broke its 50-day SMA. On...
New Highs Coming or Will We Collapse? What Say You, Fed Chief Powell?
This will be one of the most interesting quarters in recent memory. The Fed has got to choose its poison....
Flying Financials. Will It Be Enough?
Flying Financials In the recent sector rotation, basically OUT of technology and INTO anything else, Financials and Real-Estate led the...
Recovery Rally In Stock Market Offers Hope: What You Need To Watch
Major equity indexes rose on Friday after a selloff that hit the Technology sector especially hard. But this doesn’t necessarily...
Will the S&P 500 Break 5000 by September?
This week saw the major equity averages continue a confirmed pullback phase, with some of the biggest gainers in the...
DP Trading Room: Spotlight on Mega-Cap Earnings
This week we have four Magnificent Seven stocks reporting earnings. We also take a look at McDonalds (MCD) and Ford...
EQUITIES STRUGGLE AS MORE SECTORS TRY TO KEEP THE TREND AFLOAT
Good morning and welcome to this week's Flight Path. Equities had another tough week last week and we saw an...
The Legend of Zelda: Breath of the Wild gameplay on the Nintendo Switch
Dropcap the popularization of the “ideal measure” has led to advice such as “Increase font size for large screens and...
Shadow Tactics: Blades of the Shogun Review
I should be incapable of drawing a single stroke at the present moment; and yet I feel that I never...
